Arrowstreet Capital, Limited Partnership Crispr Therapeutics Ag Transaction History

Arrowstreet Capital, Limited Partnership

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $1.26 Million - $2.15 Million	29,162 New	29,162 $1.77 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $3.3 Million - $5.24 Million	-47,100 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$110.2 - $156.64 $3.74 Million - $5.31 Million	-33,900 Reduced 41.85%	47,100 $5.27 Million
Q2 2021 Aug 13, 2021	BUY	$100.84 - $161.89 $8.17 Million - $13.1 Million	81,000 New	81,000 $13.1 Million
Q4 2020 Feb 12, 2021	SELL	$79.67 - $173.23 $500,407 - $1.09 Million	-6,281 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$78.5 - $100.64 $493,058 - $632,119	6,281 New	6,281 $525,000
Q2 2020 Aug 12, 2020	SELL	$38.5 - $76.05 $10 Million - $19.8 Million	-260,996 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$33.68 - $62.53 $5.29 Million - $9.83 Million	157,196 Added 151.44%	260,996 $11.1 Million
Q4 2019 Feb 13, 2020	BUY	$36.68 - $73.13 $3.81 Million - $7.59 Million	103,800 New	103,800 $6.32 Million

489

57.9M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.1B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.